Inspire Medical Systems (NYSE:INSP) – Analysts at Svb Leerink raised their FY2019 EPS estimates for shares of Inspire Medical Systems in a research note issued to investors on Wednesday, November 6th. Svb Leerink analyst R. Newitter now expects that the company will earn ($1.56) per share for the year, up from their previous forecast of ($1.65). Svb Leerink also issued estimates for Inspire Medical Systems’ Q4 2019 earnings at ($0.55) EPS, FY2020 earnings at ($1.54) EPS and FY2021 earnings at ($1.34) EPS.
Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.09. Inspire Medical Systems had a negative return on equity of 18.32% and a negative net margin of 40.36%. The firm had revenue of $20.86 million for the quarter, compared to analysts’ expectations of $19.15 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. Inspire Medical Systems’s revenue for the quarter was up 59.8% compared to the same quarter last year.
Shares of NYSE INSP opened at $64.05 on Friday. The stock’s 50 day moving average price is $58.89 and its two-hundred day moving average price is $60.15. Inspire Medical Systems has a 52-week low of $35.43 and a 52-week high of $71.71. The stock has a market capitalization of $1.45 billion, a P/E ratio of -42.70 and a beta of 1.22. The company has a quick ratio of 20.05, a current ratio of 20.46 and a debt-to-equity ratio of 0.16.
In other news, CEO Timothy P. Herbert sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $70.00, for a total transaction of $700,000.00. Also, Director Mudit K. Jain sold 2,240 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $66.84, for a total value of $149,721.60. The disclosure for this sale can be found here. Insiders have sold 191,790 shares of company stock valued at $12,433,812 over the last ninety days. Corporate insiders own 12.10% of the company’s stock.
Several large investors have recently bought and sold shares of the company. TimesSquare Capital Management LLC grew its holdings in shares of Inspire Medical Systems by 5.5% during the third quarter. TimesSquare Capital Management LLC now owns 541,550 shares of the company’s stock valued at $33,045,000 after purchasing an additional 28,285 shares during the last quarter. SG Americas Securities LLC bought a new position in Inspire Medical Systems in the 3rd quarter worth approximately $943,000. First Trust Advisors LP bought a new position in Inspire Medical Systems in the 3rd quarter worth approximately $3,401,000. California Public Employees Retirement System grew its holdings in Inspire Medical Systems by 11.3% in the 3rd quarter. California Public Employees Retirement System now owns 23,666 shares of the company’s stock worth $1,444,000 after buying an additional 2,401 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Inspire Medical Systems by 10.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 7,023 shares of the company’s stock worth $428,000 after buying an additional 660 shares in the last quarter. 83.05% of the stock is owned by institutional investors.
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Read More: What is the market perform rating?
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.